Exact Sciences (EXAS): Among Billionaire George Soros' Small-Cap Stocks with Huge Upside Potential

We recently published a list of Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against Billionaire George Soros’ other small-cap stocks with huge upside potential.

When a legendary investor like George Soros makes a move, Wall Street pays attention. However, most of the limelight is taken by mega-cap stocks, with no one paying heed to the many small-cap stocks that form an important part of Soros’ portfolio.

Digging out these small-cap stocks is important. In some cases, these are the mega-cap stocks of the future. In other cases, these provide amazing returns in a very short period of time. The key is to get in early. And what better way to get in early than to do it when the big guys do.

We therefore decided to compile a list of stocks in billionaire George Soros’ portfolio that have the most upside. To come up with our list of billionaire George Soros’ 10 Small-Cap stocks with huge upside potential, we first looked at his top 50 stock holdings. We then filtered out the companies to look at only the ones with a market cap below $10 billion.

After arriving at his top small-cap holdings list, we then looked at the median analyst price targets on those stocks and then ranked them by their upside potential.

Exact Sciences Corporation (NASDAQ:EXAS)

Exact Sciences Corporation (NASDAQ:EXAS) operates as a cancer screening and diagnostic test products provider. The company provides Cologuard, Oncotype DX Breast DCIS Score Test, OncoExTra Test for tumor profiling, Riskguard Test, Oncotype DX Breast Recurrence Score Test, and Oncotype DX Colon Recurrence Score Test. According to the median analyst price target, the stock still has an upside of 47.23%.

On April 22, the firm announced the launch of its new test, Oncodetect. This new test detects the molecular residual disease (MRD) among multiple solid tumors. According to the company, this test provides clear results, ‘detected’ or ‘not detected’, along with the quantitative data to facilitate treatment.

Brian Baranick, Executive Vice President and General Manager Precision Oncology at Exact Sciences (NASDAQ:EXAS), said:

“Exact Sciences is transforming cancer care by delivering tests that provide the clarity patients and physicians need to make confident decisions,… Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care.”

RBC Capital Markets started coverage of Exact Sciences (NASDAQ:EXAS) last month. The research firm assigned a Sector Perform rating to the stock with a price target of $52, citing growth potential in the oncology screening sector of liquid biopsy.

Overall, EXAS ranks 8th on our list of billionaire George Soros’ small-cap stocks with huge upside potential. While we acknowledge the potential of EXAS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than EXAS but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.